CoLucid Pharmaceuticals Inc (CLCD)

Sector:
HEALTH CARE
Industry:
BIOTECHNOLOGY & LIFE SCIENCES
SIC:
PHARMACEUTICAL PREPARATIONS
CEO:
Thomas P. Mathers
Employees:
7
222 THIRD STREET, CAMBRIDGE, MA 02142
781-365-2596

• *** This stock is shown as delisted in our database. *** If you think this isn't correct then please let us know

CoLucid Pharmaceuticals, Inc., a biopharmaceutical company, develops small molecules for the acute treatment of migraine. Its lead product candidate is Lasmiditan, an oral tablet that is in Phase III clinical program for the acute treatment of mig...

Data derived from most recent annual or quarterly report
Market Cap 895.454 Million Shares Outstanding19.247 Million Avg 30-day Volume 245.84 Thousand
P/E Ratio0.0 Dividend Yield0.0 EPS-0.79
Price to Revenue0.0 Debt to Equity0.0 EBITDA-52.91 Million
Price to Book Value8.11 Operating Margin0.0 Enterprise Value634.082 Million
Current Ratio11.301 EPS Growth1.81 Quick Ratio11.215
1 Yr BETA 1.4997 52-week High/Low 0.0 / Profit Margin0.0
Operating Cash Flow Growth-239.1452 Free Cash Flow to Firm (FCFF) TTM -33.382 Million Free Cash Flow to Equity (FCFE) TTM-37.448 Million
Altman Z-Score39.7826
View SEC Filings from CLCD instead.

View recent insider trading info

CoLucid Pharmaceuticals Inc YCharts
Yahoo! Finance finviz
SEC Web Site SEC DEF 14A Filings

Funds Holding CLCD (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
Click for Additional Filters
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding CLCD

Download CSV

Active Schedule 13D and 13G filings

Please sign in first

Recent Filings

Financial Reporting

Ownership

  • 4: filed on 2017-03-01 by COLUCID PHARMACEUTICALS, INC.
  • 4: filed on 2017-03-01 by COLUCID PHARMACEUTICALS, INC.
  • 4: filed on 2017-03-01 by COLUCID PHARMACEUTICALS, INC.
  • 4: filed on 2017-03-01 by COLUCID PHARMACEUTICALS, INC.
  • 4: filed on 2017-03-01 by COLUCID PHARMACEUTICALS, INC.
  • 4: filed on 2017-03-01 by COLUCID PHARMACEUTICALS, INC.
  • 4: filed on 2017-03-01 by COLUCID PHARMACEUTICALS, INC.
  • 4: filed on 2017-03-01 by COLUCID PHARMACEUTICALS, INC.
  • 4: filed on 2017-03-01 by COLUCID PHARMACEUTICALS, INC.
  • 4: filed on 2017-03-01 by COLUCID PHARMACEUTICALS, INC.

    • Events (8k)

  • 8-K: filed on 2017-03-01:
    Item 2.01: Completion of Acquisition or Disposition of Assets
    Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
    Item 3.03: Material Modifications to Rights of Security Holders
    Item 5.01: Changes in Control of Registrant
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
    Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2017-01-18:
    Item 1.01: Entry into a Material Definitive Agreement
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2016-11-09:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2016-10-12:
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2016-09-09:
    Item 7.01: Regulation FD Disclosure
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2016-09-08:
    Item 8.01: Other Events
  • 8-K: filed on 2016-08-10:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2016-05-11:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2016-05-11:
    Item 5.07: Submission of Matters to a Vote of Security Holders
  • 8-K: filed on 2016-03-15:
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
    Item 9.01: Financial Statements and Exhibits

    • Proposed Sales (Form 144)

    Proxy

    Prospectus

    All

    Open Market Buys/Sells Last 60 Days

    Open Market Buys (P)

    none

    Open Market Sells (S)

    none

    Exercise Derivative Conversion (M)

    none

    Current/Former Insiders

    Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

    LILLY ELI & CO

    PROCAR ACQUISITION CORP

    • 10% Owner
    		 100 2017-03-01 0

    PAPPAS ARTHUR M

    A.M. PAPPAS LIFE SCIENCE VENTURES III, L.P.

    PV III CEO FUND, L.P.

    PAPPAS CAPITAL, LLC

    • Director
    • 10% Owner
    		 No longer subject to file 2017-03-01 0

    CORRIGAN MARK

    • Director
    		 No longer subject to file 2017-03-01 0

    WHITE MARVIN L

    • Director
    		 No longer subject to file 2017-03-01 0

    LAWTON ALISON FRANCES

    • Director
    		 No longer subject to file 2017-03-01 0

    DALLAS MATTHEW D CHIEF FINANCIAL OFFICER

    • Officer
    		 No longer subject to file 2017-03-01 0

    MARENGERE LUC

    TVM LIFE SCIENCE VENTURES VII L.P.

    • Director
    • 10% Owner
    		 No longer subject to file 2017-03-01 0

    HOGAN LINDA C. HEAD, BUS. DEV. AND STRATEGY

    • Officer
    		 No longer subject to file 2017-03-01 0

    KUCA BERNICE HEAD,CLIN. AND REG. OPERATIONS

    • Officer
    		 No longer subject to file 2017-03-01 0

    MATHERS THOMAS P. CHIEF EXECUTIVE OFFICER

    • Officer
    • Director
    		 No longer subject to file 2017-03-01 0

    SKWIERCZYNSKI RAYMOND HEAD,PHARMACEUTICAL OPERATIONS

    • Officer
    		 No longer subject to file 2017-03-01 0

    MARENGERE LUC

    • Director
    • 10% Owner
    		 0 2017-01-03 0

    DOMAIN PARTNERS VI, L.P.

    BLAIR JAMES C

    DOVEY BRIAN H

    TREU JESSE I

    VITULLO NICOLE

    • 10% Owner
    		 No longer subject to file 2016-09-09 0

    NOVO A/S

    • 10% Owner
    		 3,156,563 2016-09-09 0

    DP VI ASSOCIATES, L.P.

    BLAIR JAMES C

    DOVEY BRIAN H

    TREU JESSE I

    VITULLO NICOLE

    • 10% Owner
    		 3,039 2016-08-01 0

    PAPPAS ARTHUR M

    • Director
    • 10% Owner
    		 0 2016-05-10 0

    RUPNIAK NADIA VP-RESEARCH AND DEVELOPMENT

    • Officer
    		 14,145 2015-05-13 0

    DOMAIN PARTNERS VI, L.P.

    BLAIR JAMES C

    DOVEY BRIAN H

    TREU JESSE I

    SCHOEMAKER KATHLEEN K

    VITULLO NICOLE

    • Director
    • 10% Owner
    		 2,245,902 2015-05-11 0

    DP VI ASSOCIATES, L.P.

    BLAIR JAMES C

    DOVEY BRIAN H

    TREU JESSE I

    SCHOEMAKER KATHLEEN K

    VITULLO NICOLE

    • Director
    • 10% Owner
    		 3,519 2015-05-11 0

    MARKHAM RICHARD J

    CARE CAPITAL III LLC

    CARE CAPITAL INVESTMENTS III L.P.

    CARE CAPITAL OFFSHORE INVESTMENTS III LP

    • Director
    • 10% Owner
    		 1,545,539 2015-05-11 0

    TREU JESSE I

    • Director
    • 10% Owner
    		 0 2015-05-05 0

    EDWARDS MARTIN

    • Director
    		 0 2015-05-05 0

    Insider Transactions Last 60 Days

    Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
    Disposed    		 Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days
    No current insider transactions

    * -

    Transaction Code Definitions
    Code Definition
    A Grant, award or other acquisition pursuant to Rule 16b-3(d)
    C Conversion of derivative security
    D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
    E Expiration of short derivative position
    F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
    G Bona fide gift
    H Expiration (or cancellation) of long derivative position with value received
    I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
    J Other acquisition or disposition
    L Small acquisition under Rule 16a-6
    M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
    O Exercise of out-of-the-money derivative security
    P Open market or private purchase of non-derivative or derivative security
    S Open market or private sale of non-derivative or derivative security
    U Disposition pursuant to a tender of shares in a change of control transaction
    W Acquisition or disposition by will or the laws of descent and distribution
    X Exercise of in-the-money or at-the-money derivative security
    Z Deposit into or withdrawal from voting trust

    IBR Securities Loan Availability

    Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

    Security Date/Time Rebate Rate Fee Rate Shares Available

    Current Active Short Positions

    Holder Issuer Net Short Position Position Date Origin

    No recent transactions

    *** To see all congressional transactions (since 2022) for this stock, please use the congressional transaction search page***

    WhaleWisdom Logo

    Elevate your investments